Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales
| Autor: | Tamima Jisr, Wael Zorkot, Rima Moghnieh, Hassan El Masri, Marwa Jadayel, Loubna Sinno, Marie Joe Dib, Rawad Lakkis, Tasnim Omar, Dania Abdallah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Multivariate analysis Science 030106 microbiology Diseases Microbial Sensitivity Tests Meropenem Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Statistical significance medicine Odds Ratio Humans 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over Inpatients Multidisciplinary Framingham Risk Score business.industry Incidence (epidemiology) Incidence Health care Enterobacteriaceae Infections Regression analysis Odds ratio Middle Aged Anti-Bacterial Agents Cephalosporins Hospitalization Carbapenem-Resistant Enterobacteriaceae chemistry Risk factors ROC Curve Area Under Curve Case-Control Studies Medicine Female business Ertapenem medicine.drug |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021) |
| ISSN: | 2045-2322 |
| Popis: | In this study, we determined the incidence and risk factors of Carbapenem-resistant Enterobacterales (CRE) acquisition in inpatients with 3rd generation cephalosporin-resistant (3GCR) Enterobacterales at a tertiary-care hospital in Lebanon, and suggested a risk prediction score for it. This is a retrospective matched case–control study of inpatients with 3GCR Enterobacterales that are carbapenem resistant (cases) versus those with carbapenem-sensitive isolates (controls). Data analysis was performed on IBM SPSS program, version 23.0 (Armonk, NY, USA: IBM Corp.). Categorical variables were compared between cases and controls through bivariate analysis and those with statistical significance (P 2 = 0.789, P = 0.041). Multivariate analysis of matched data revealed that the history of cerebrovascular disease (OR 1.96; 95% CI 1.04–3.70; P = 0.039), hematopoietic cells transplantation (OR 7.75; 95% CI 1.52–39.36; P = 0.014), presence of a chronic wound (OR 3.38; 95% CI 1.73–6.50; P P = 0.01), nosocomial site of acquisition of the organism in question (OR 2.68; 95% CI 1.51–4.73; P = 0.001), and the prior use of meropenem within 3 months of CRE acquisition (OR 5.70; 95% CI 2.61–12.43; P P = 0.106), unlike imipenem (r = − 0.868, P = 0.056) and ertapenem (r = 0.385, P = 0.522). Patients with a score of ≥ 5 points in our model were likely to acquire CRE. Only meropenem was associated with CRE carriage. Our proposed risk prediction score would help target surveillance screening for CRE amongst inpatients at the time of hospital admission and properly guide clinicians on using anti-CRE therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink